BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Zydus Lifesciences Gets US FDA Approval for Deflazacort Oral Suspension

Synopsis:


Zydus Lifesciences has won final US FDA approval for its Deflazacort oral suspension (22.75 mg/mL), targeting treatment of Duchenne Muscular Dystrophy in ages 5+, to be manufactured in Doppel, Italy.


Source:
Zydus Lifesciences Press Release (NSE Exchange Fillings) | Published on Oct 07, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

Zydus Lifesciences News Today

As quoted in the press release of Zydus Lifesciences (NSE Exchange Filings), the company stated that it has received final approval from the United States Food and Drug Administration (US FDA) for its generic Deflazacort oral suspension product. The approved strength of 22.75 mg/ml will be indicated for Duchenne Muscular Dystrophy (DMD) in patients 5 years of age and older. Additionally, the company confirmed that product manufacturing will take place at its facility in Doppel, Italy.

Also read: KEC International Bags Orders Worth Rs 1,102 Crore Across Businesses

ZYDUS LIFESCIENCES LTD

Trade

990.2-4.45 (-0.44 %)

Updated - 07 October 2025
1002.00day high
DAY HIGH
988.10day low
DAY LOW
364990
VOLUME (BSE)

Key Takeaways

  • Approval granted for Deflazacort oral suspension 22.75 mg/ml.

  • The medication is indicated for treating DMD in patients aged five and above.

  • Manufacturing will take place at the company’s facility in Italy.

  • The approval expands Zydus Lifesciences’ generic product portfolio.

Therapeutic Relevance Of Deflazacort

Deflazacort is categorized as a corticosteroid and is frequently prescribed for Duchenne Muscular Dystrophy, a serious genetic disorder that causes progressive muscle loss. Deflazacort works by decreasing inflammation and altering immune system targeting in the body to help manage progression of DMD in affected individuals. 

Treatments like Deflazacort continue to be an integral part of the standard of care for DMD, delaying progression of muscle weakness and improving patient health and quality of life. The treatment is the first alternative treatment option for patients and healthcare providers in the United States.

Significance For Zydus Lifesciences

The recent approval is another addition to Zydus Lifesciences’ fast-growing presence of US FDA-approved products. Zydus Lifesciences has made a sustained effort to grow its presence in regulated markets like the US and this developments further strengthens it within the specialized therapy area. 

It reiterates the company’s commitment to developing therapies for uncommon diseases and grows the long-term pipeline of generic products. The ramping up of the Deflazacort oral suspension product will enhance the company’s overall strategy for revenue diversification and its overall presence in the neuromuscular disorder area.

Share Price Overview

Zydus Lifesciences share price stands at ₹991.15 per share on the BSE as of 06 October 2025 at 15:30 PM IST, up by 0.95%. The market will closely monitor how this regulatory development influences investor sentiment and trading activity in the short term.

Market Outlook

Though receiving regulatory approval is a key step, the full impact on the market is dependent on multiple market drivers including product uptake speed, competition from current therapies, and US generics market pricing. The US FDA approval of Deflazacort oral suspension allows Zydus Lifesciences to enhance its product portfolio, improving its competitive position in the neuromuscular treatment market.

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text